ReviewACS omega2021
Extracellular Nanovesicles: From Intercellular Messengers to Efficient Drug Delivery Systems.
Review in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy.ACS measurement science au · 2025Review
- Advancing therapeutic efficacy: nanovesicular delivery systems for medicinal plant-based therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Quantitative Detection of Biological Nanovesicles in Drops of Saliva Using Microcantilevers.ACS applied materials & interfaces · 2024Article
- Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment.International journal of nanomedicine · 2024Review
- Unlocking Exosome-Based Theragnostic Signatures: Deciphering Secrets of Ovarian Cancer Metastasis.ACS omega · 2023Review
- Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances.Acta pharmaceutica Sinica. B · 2023Review
- Article
- A comprehensive review of the applications of bacteriophage-derived endolysins for foodborne bacterial pathogens and food safety: recent advances, challenges, and future perspective.Frontiers in microbiology · 2023Review
- MicroRNAs in T Cell-Immunotherapy.International journal of molecular sciences · 2022Review
- Biomimetic Nanovesicles-Sources, Design, Production Methods, and Applications.Pharmaceutics · 2022Review
- Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics.Bioactive materials · 2022Review
- Immune Modulation as a Key Mechanism for the Protective Effects of Remote Ischemic Conditioning After Stroke.Frontiers in neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Nanosized extracellular vesicles (nEV) are released by all the eukaryotic cells into the extracellular spaces. They serve as crucial mediators of intercellular communication, and their presence has been detected in a variety of body fluids. nEV carry nucleic acids, lipids, proteins, and metabolites from the donor cells and transfer them to the recipient cells in the vicinity or distant locations to cause changes in their biological phenotypes. This very property of nEV makes them a suitable carrier of the drugs for therapeutic applications. The use of nEV as a drug delivery system offers several advantages over synthetic nanoparticles, including biocompatibility, natural targeting ability, and long-term safety. Further, nEV can be isolated from various biological sources, quickly loaded with the drug of choice, and modified to further enhance their utility as targeted drug delivery vehicles. Here we review these aspects of nEV and discuss the parameters that should be kept in mind while choosing the nEV source, drug loading method, and surface modification strategies. We also discuss the challenges associated with the nEV-based drug delivery platforms that must be overcome before realizing their full potential in clinical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.